시장보고서
상품코드
1147338

성기 헤르페스 시장 : 시장 인사이트, 역학, 시장 예측(-2032년)

Genital Herpes - Market Insight, Epidemiology And Market Forecast - 2032

발행일: | 리서치사: DelveInsight Business Research LLP | 페이지 정보: 영문 192 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

주요 8개국의 성기 헤르페스 시장 규모는 2021년에 11억 2,500만 달러로 평가되었습니다. 이 시장은 앞으로도 한층 더 확대될 것으로 예측됩니다.

주요 8개국의 성기 헤르페스(Genital Herpes)시장에 대해 조사했으며, 시장 개요와 함께 역학, 환자 동향, 새로운 치료법, 2032년까지 시장 규모 예측 및 의료 미충족 요구 등의 정보를 제공합니다.

목차

제1장 주요 인사이트

제2장 보고서 서론

제3장 성기 헤르페스 시장 개요

제4장 성기 헤르페스 개요

제5장 역학과 시장 조사 방법

제6장 질환의 배경과 개요

  • 서론
  • 성기 헤르페스의 증상
  • 성기 헤르페스의 원인과 위험 요인
  • 성기 헤르페스의 병태생리
  • 성기 헤르페스의 단계
  • 성기 헤르페스의 전염과 감염
  • 성기 헤르페스의 합병증
  • 성기 헤르페스의 진단

제7장 치료

제8장 역학과 환자수

  • 주요 조사 결과
  • 가정과 근거 8MM
  • 주요 8개국의 역학 시나리오
  • 미국의 역학 시나리오
  • EU 5개국의 역학 시나리오
  • 일본의 역학 시나리오
  • 중국의 역학 시나리오

제9장 성기 헤르페스 환자 동향

제10장 성기 헤르페스 임상시험에서의 주요 엔드포인트

제11장 새로운 치료법

제12장 성기 헤르페스 : 주요 8개국 시장 분석

  • 주요 조사 결과
  • 시장 전망
  • 주요 8개국의 성기 헤르페스 시장 규모
  • 미국의 성기 헤르페스 시장 규모
  • EU 5개국의 성기 헤르페스 시장 규모
  • 일본의 성기 헤르페스 시장 규모
  • 중국의 성기 헤르페스 시장 규모

제13장 시장 접근과 상환

제14장 KOL(Key Opinion Leader)의 견해

제15장 SWOT 분석

제16장 미충족 요구

제17장 부록

제18장 DelveInsight의 서비스 내용

제19장 면책사항

제20장 DelveInsight에 대해

LSH 22.11.11

DelveInsight's "Genital Herpes- Market Insight, Epidemiology and Market Forecast-2032" report delivers an in-depth understanding of Genital Herpes, historical and forecasted epidemiology as well as the Genital Herpes trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan and China.

The Genital Herpes market report provides emerging drugs, Genital Herpes market share of the individual cancer types, current and forecasted Genital Herpes market size from 2019 to 2032 segmented by eight major markets. The Report also covers current Genital Herpes unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
  • China

Study Period: 2019-2032.

Genital Herpes Understanding and Treatment Algorithm

The DelveInsight's Genital Herpes epidemiology report gives a thorough understanding of Genital Herpes by including details such as overview of Genital Herpes, advantages, disadvantages and available therapies. Comprehensive epidemiology insight of Genital Herpes. It is a chronic sexually transmitted infection (STI) characterized by recurrent, self-limited genital ulcers caused by herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2). It can cause blisters and open sores (lesions) in the genital area, but it can also be asymptomatic, meaning a person does not show symptoms.

Genital herpes can be asymptomatic or have mild symptoms that go unrecognized. When symptoms occur, genital herpes is characterized by one or more genital or anal blisters or ulcers. Additionally, symptoms of a new infection often include fever, body aches, and swollen lymph nodes. After an initial episode, which can be severe, symptoms may recur. Genital herpes caused by HSV-1 typically does not recur frequently. With HSV-2, recurrent symptoms are common; however, recurrences are often less severe than the first episode and tend to decrease over time.

Currently, there is no cure for genital herpes. Treatment with prescription antiviral medications may help sores heal sooner during an initial outbreak, lessen the severity and duration of symptoms in recurrent outbreaks, reduce the frequency of recurrence, and minimize the chance of transmitting the herpes virus to another. Antiviral medications used for genital herpes include acyclovir, valacyclovir, and famciclovir. These drugs can be used for episodic treatment or long-term suppressive therapy

Genital Herpes Epidemiology

The epidemiology section provides the insights about historical and current patient pool and forecasted trend for each eight major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings:

The disease epidemiology covered in the report provides historical as well as forecasted Genital Herpes epidemiology scenario in the 8MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), Japan, and China from 2019 to 2032.

In 2021, the total diagnosed Genital Herpes cases per year were 1.6 million in the 8MM which are expected to grow during the study period, i.e., 2019-2032.

The disease epidemiology covered in the report provides historical as well as forecasted Genital Herpes epidemiology [segmented as Prevalent HSV infected cases, Symptomatic Genital Herpes cases per year, Gender-specific cases of Genital Herpes, Diagnosed Genital Herpes cases per year, Total recurrent cases of Genital Herpes, and Treated patient pool of Genital Herpes] in the 8MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan and China from 2019 to 2032.

Country Wise- Genital Herpes Epidemiology

The epidemiology segment also provides the Genital Herpes epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.

Genital Herpes Drug Chapters

The drug chapter segment of the Genital Herpes report encloses the detailed analysis of Genital Herpes marketed drugs and late-stage (Phase III and Phase II) pipeline drugs. It also helps to understand the Genital Herpes clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Genital Herpes treatment.

Genital Herpes Market Outlook

The Genital Herpes market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Genital Herpes market trends by analyzing the impact of current therapies on the market, unmet needs, and demand of better technology.

This segment gives a thorough detail of Genital Herpes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Genital Herpes in 8MM is expected to witness a major change in the study period 2019-2032.

Key Findings

The Genital Herpes market size in the 8MM is expected to change during the study period 2019-2032. The Genital Herpes therapeutic market in the eight major markets is expected to increase during the study period (2019-2032). In 2021, the total market size of Genital Herpes was approximately USD 1,125 million which is expected to rise during the study period (2019-2032).

The United States Market Outlook

The total market size of Genital Herpes in the United States accounted for USD 417 million in 2021 which is expected to rise during the study period (2019-2032).

EU-5 Countries: Market Outlook

In EU5, the total market size of Genital Herpes was USD 342 million in 2021, which is expected to rise during the study period (2019-2032).

Japan Market Outlook

In Japan, the total market size of Genital Herpes was USD 69 million in 2021, which is expected to rise during the study period (2019-2032).

China Market Outlook

In China, the total market size of Genital Herpes was USD 296 million in 2021, which is expected to rise during the study period (2019-2032).

Genital Herpes Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Genital Herpes market or expected to get launched in the market during the study period 2019-2032. The analysis covers Genital Herpes market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Genital Herpes Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses key players involved in developing Genital Herpes.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing patent details, and other information for emerging Genital Herpes.

Reimbursement Scenario in Genital Herpes

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Genital Herpes domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Genital Herpes market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitively and Market Intelligence analysis of the Genital Herpes Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers a detailed overview of the development of Genital Herpes, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies.
  • Comprehensive insight has been provided into the Genital Herpes epidemiology and treatment in the 8MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Genital Herpes is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Genital Herpes market; historical and forecasted is included in the report, covering drug outreach in the 8MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Genital Herpes market.

Report Highlights:

  • In the coming years, the Genital Herpes market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Genital Herpes R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Genital Herpes. Launch of emerging therapies, will significantly impact the Genital Herpes market.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Genital Herpes Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Genital Herpes Pipeline Analysis
  • Genital Herpes Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Genital Herpes Report Key Strengths

  • 11 Years Forecast
  • 8MM Coverage
  • Genital Herpes Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Genital Herpes Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness

Key Questions

Market Insights:

  • What was the Genital Herpes Market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Genital Herpes total market size as well as market size by therapies across the 8MM during the study period (2019-2032)?
  • What are the key findings pertaining to the market across the 8MM and which country will have the largest Genital Herpes market size during the study period (2019-2032)?
  • At what CAGR, the Genital Herpes market is expected to grow in the 8MM during the study period (2019-2032)?
  • What would be the Genital Herpes market outlook across the 8MM during the study period (2019-2032)?
  • What would be the Genital Herpes market growth till 2032 and what will be the resultant market size in the year 2032?
  • Genital Herpes patient types/pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?

Epidemiology Insights:

  • What is the challenges and unmet needs of the Genital Herpes?
  • What are the key factors driving the epidemiology trend for eight major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Genital Herpes patient pool in the eight major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the forecasted patient pool of Genital Herpes in the 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What will be the growth opportunities in the 8MM with respect to the patient population pertaining to Genital Herpes?
  • Out of all the 8MM countries, which country would have the highest number of diagnosed Genital Herpes cases per year during the study period (2019-2032)?
  • At what CAGR the population is expected to grow by 8MM during the study period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the marketed Genital Herpes and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Genital Herpes?
  • How many therapies are in-development by each company for Genital Herpes treatment?
  • How many are emerging Genital Herpes in mid-stage, and late stage of development for Genital Herpes treatment?
  • What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Genital Herpes?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Genital Herpes and its status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for Genital Herpes?
  • What are the global historical and forecasted markets of Genital Herpes?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Genital Herpes market
  • To understand the future market competition in the Genital Herpes market and Insightful review of the key unmet needs
  • Organize sales and marketing efforts by identifying the best opportunities for Genital Herpes in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), Japan, and China
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Genital Herpes market
  • To understand the future market competition in the Genital Herpes market

Table of Contents

1. Key Insights

2. Report Introduction

3. Genital Herpes Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of Genital Herpes in 2019
  • 3.2. Market Share (%) Distribution of Genital Herpes in 2032

4. Executive Summary of Genital Herpes

  • 4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

  • 6.1. Introduction
  • 6.2. Symptoms of Genital Herpes
  • 6.3. Causes and Risk Factors of Genital Herpes
  • 6.4. Pathophysiology of Genital Herpes
  • 6.5. Stages of Genital Herpes
    • 6.5.1. The prodrome stage
    • 6.5.2. The blister stage
    • 6.5.3. The ulcer stage
    • 6.5.4. The healing stage
  • 6.6. Genital Herpes Transmission and Infection
    • 6.6.1. Primary herpes genitalis
    • 6.6.2. Non-primary infections
    • 6.6.3. Recurrent herpes genitalis
    • 6.6.4. Asymptomatic genital viral shedding
    • 6.6.5. Virus transmission
  • 6.7. Complications of Genital Herpes
  • 6.8. Diagnosis of Genital Herpes
    • 6.8.1. Viral culture
    • 6.8.2. Polymerase chain reaction (PCR) testing
    • 6.8.3. Serologic testing
    • 6.8.4. Diagnostic algorithm
    • 6.8.5. Differential diagnosis
    • 6.8.6. Diagnostic Guidelines

7. Treatment

  • 7.1. First Clinical Episode
  • 7.2. Episodic Therapy
  • 7.3. Suppressive Therapy
  • 7.4. Severe Disease
  • 7.5. Other Therapies
  • 7.6. Treatment Algorithm
  • 7.7. Treatment Guidelines for Genital Herpes
    • 7.7.1. WHO Guidelines for the Treatment of Genital HSV, 2016
    • 7.7.2. 2015 CDC STD Guidelines on Herpes Infection
    • 7.7.3. 2017 European Guidelines for the Management of Genital Herpes

8. Epidemiology and Patient Population

  • 8.1. Key Findings
  • 8.2. Assumptions and Rationale 8MM
  • 8.3. Epidemiology Scenario in the 8MM
    • 8.3.1. Prevalent HSV infected cases
    • 8.3.2. Symptomatic Cases of Genital Herpes per year
    • 8.3.3. Gender-specific Cases of Genital Herpes
    • 8.3.4. Diagnosed Cases of Genital Herpes per Year
    • 8.3.5. Total Recurrent cases of Genital Herpes
    • 8.3.6. Treated Patient Pool of Genital Herpes
  • 8.4. Epidemiology Scenario in the US
    • 8.4.1. Prevalent HSV infected cases
    • 8.4.2. Symptomatic Cases of Genital Herpes per year
    • 8.4.3. Gender-specific Cases of Genital Herpes
    • 8.4.4. Diagnosed Cases of Genital Herpes per Year
    • 8.4.5. Total Recurrent cases of Genital Herpes
    • 8.4.6. Treated Patient Pool of Genital Herpes
  • 8.5. Epidemiology Scenario in the EU 5
    • 8.5.1. Prevalent HSV infected cases
    • 8.5.2. Symptomatic Cases of Genital Herpes per year
    • 8.5.3. Gender-specific Cases of Genital Herpes
    • 8.5.4. Diagnosed Cases of Genital Herpes per Year
    • 8.5.5. Total Recurrent cases of Genital Herpes
    • 8.5.6. Treated Patient Pool of Genital Herpes
  • 8.6. Epidemiology Scenario in Japan
    • 8.6.1. Prevalent HSV infected cases of Genital Herpes
    • 8.6.2. Symptomatic Cases of Genital Herpes per year
    • 8.6.3. Gender-specific Cases of Genital Herpes
    • 8.6.4. Diagnosed Cases for Genital Herpes per Year
    • 8.6.5. Total Recurrent cases of Genital Herpes
    • 8.6.6. Treated Patient Pool of Genital Herpes
  • 8.7. Epidemiology Scenario in China
    • 8.7.1. Prevalent HSV infected cases of Genital Herpes
    • 8.7.2. Symptomatic Cases of Genital Herpes per year
    • 8.7.3. Gender-specific Cases of Genital Herpes
    • 8.7.4. Diagnosed Cases of Genital Herpes per Year
    • 8.7.5. Total Recurrent cases of Genital Herpes
    • 8.7.6. Treated Patient Pool of Genital Herpes

9. Patient Journey of Genital Herpes

10. Key Endpoints in Genital Herpes Clinical Trials

11. Emerging Therapies

  • 11.1. Key Competitors
  • 11.2. AIC-316 (pritelivir): AiCuris
    • 11.2.1. Product description
    • 11.2.2. Other developmental activities
    • 11.2.3. Clinical development
    • 11.2.4. Safety and efficacy
  • 11.3. UB-621: United BioPharma
    • 11.3.1. Product description
    • 11.3.2. Other developmental activities
    • 11.3.3. Clinical development
  • 11.4. HDIT101: Heidelberg ImmunoTherapeutics
    • 11.4.1. Product description
    • 11.4.2. Clinical development
    • 11.4.3. Safety and efficacy
  • 11.5. SIMPLIRIX (GSK208141)
    • 11.5.1. Product description
  • 11.6. GEN-003: Genocea Biosciences
    • 11.6.1. Product description
    • 11.6.2. Other developmental activities
  • 11.7. HerpV (AG-707): Agenus
    • 11.7.1. Product description
    • 11.7.2. Other development activities
  • 11.8. VCL-HB01: Fresh Tracks Therapeutics
    • 11.8.1. Product description
    • 11.8.2. Other development activities
  • 11.9. SP-0148: Sanofi
    • 11.9.1. Product description

12. Genital Herpes : 8 Major Market Analysis

  • 12.1. Key Findings
  • 12.2. Market Outlook
  • 12.3. Market Size of Genital Herpes in the 8MM
    • 12.3.1. Total Market Size of Genital Herpes
    • 12.3.2. Market Size of Genital Herpes by Therapies
  • 12.4. Market Size of Genital Herpes in the US
    • 12.4.1. Total Market Size of Genital Herpes
    • 12.4.2. Market Size of Genital Herpes by Therapies
  • 12.5. Market Size of Genital Herpes in the EU 5
    • 12.5.1. Total Market Size of Genital Herpes
    • 12.5.2. Market Size of Genital Herpes by Therapies
  • 12.6. Market Size of Genital Herpes in Japan
    • 12.6.1. Total Market Size of Genital Herpes
    • 12.6.2. Market Size of Genital Herpes by Therapies
  • 12.7. Market Size of Genital Herpes in China
    • 12.7.1. Total Market Size of Genital Herpes
    • 12.7.2. Market Size of Genital Herpes by Therapies

13. Market Access and Reimbursement

  • 13.1. Reimbursement

14. KOL Views

15. SWOT Analysis

16. Unmet Needs

17. Appendix

  • 17.1. Acronyms and Abbreviations
  • 17.2. Bibliography
  • 17.3. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제